1006036-87-8

Basic information

• Product Name: 4-[1-[[[2,5-Dimethyl-4-[[4-(trifluoromethyl)phenyl]methyl]-3-thienyl]carbonyl]amino]cyclopropyl]benzoic acid
• Synonyms: 4-[1-[[[2,5-Dimethyl-4-[[4-(trifluoromethyl)phenyl]methyl]-3-thienyl]carbonyl]amino]cyclopropyl]benzoic acid;MK-2894;4-{1-[({2,5-Dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid
• CAS NO: 1006036-87-8
• Molecular Formula: C₂₅H₂₂F₃NO₃S
• Molecular Weight: 473.5072896
• Mol File: 1006036-87-8.mol

Chemical Properties

• Melting Point: 254-256℃
• Boiling Point: 569.4±50.0 °C(Predicted)
• Appearance: /
• Density: 1.39±0.1 g/cm3(Predicted)
• Solubility: Soluble in DMSO
• PKA: 4.35±0.10(Predicted)
• CAS DataBase Reference: 4-[1-[[[2,5-Dimethyl-4-[[4-(trifluoromethyl)phenyl]methyl]-3-thienyl]carbonyl]amino]cyclopropyl]benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[1-[[[2,5-Dimethyl-4-[[4-(trifluoromethyl)phenyl]methyl]-3-thienyl]carbonyl]amino]cyclopropyl]benzoic acid(1006036-87-8)
• EPA Substance Registry System: 4-[1-[[[2,5-Dimethyl-4-[[4-(trifluoromethyl)phenyl]methyl]-3-thienyl]carbonyl]amino]cyclopropyl]benzoic acid(1006036-87-8)

Safety Data

• Hazardous Substances Data: 1006036-87-8(Hazardous Substances Data)

Usage

Biological Activity

mk-2894 is a highly potent and selective inhibitor of ep4 receptor with ic50 value of 2.5 nm [1].mk-2894 is a highly selective and potent second generation ep4 antagonist with a ki of 0.56±0.1nm in the radio ligand binding assay using membranes prepared from human ep1-4 overexpressed hek 293 cell lines. and the ep4 functional assay measures the inhibition of pge2-induced camp accumulation with ic50 of 2.5±0.7nm. in the aia model and gi tolerability model in male sd rats, mk-2894 shows a dose-dependent inhibition of pain response with ed50 of 0.36 mg/kg. it also has the potent activity in inhibiting chronic pawswelling with ed50 of 0.02 mg/kg/day. overall, mk-2894 displays the desired potency, selectivity, pharmacokinetic, and gi tolerability profile for further development and represents a potential safer alternative for treating pain and inflammation than traditional nsaids and coxibs [1].

references

[1] marc blouin, yongxin han, jason burch, julie farand, christophe mellon, mireille gaudreault, mark wrona, jean-francois levesque, danielle denis, marie-claude mathieu, rino stocco, erika vigneault, alex therien, patsy clark, steve rowland, daigen xu, gary o’neill, yves ducharme and rick friesen. the discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (mk-2894), a potent and selective prostaglandin e2 subtype 4 receptor antagonist. j. med. chem. 2010, 53: 2227–2238.

Upstream product

• 1006037-11-1 methyl 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoate 

Relevant articles and documents

The discovery of 4-{l-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]- 3thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin e2 subtype 4 receptor antagonist

The discovery of highly potent and selective second generation EP4 antagonist MK-2894 (34d) is discussed. This compound exhibits favorable pharmacokinetic profile in a number of preclinical species and potent anti-inflammatory activity in several animal models of pain/inflammation. It also shows favorable GI tolerability profile in rats when compared to traditional NSAID indomethacin.

Scalable synthesis of a prostaglandin EP4 receptor antagonist

The evolution of scalable, economically viable synthetic approaches to the potent and selective prostaglandin EP4 antagonist 1 is presented. The chromatography-free synthesis of multikilogram quantities of 1 using a seven-step sequence (six in the longest

PROCESS FOR MAKING THIOPHENE CARBOXAMIDE DERIVATIVE

The invention encompasses a process for making a thiophene carboxamide derivative, which is an EP4 antagonist useful for treating pain and inflammation.

THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS

The invention is directed to thiophenecarboxamide derivatives of formulae I and II as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoi